nach oben

Erschienen in:

18.03.2024 | ORIGINAL ARTICLE

Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia

verfasst von: Qi An, Rulan Ma, Dawei Yuan, Jing Huang, Jing Luo, Yanhua Wang, Ying Pan, Pei Wang, Xiaohong Lv, Dan Pu, Lan He

Erschienen in: Clinical Rheumatology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this study was to analyze the changes in plasma fibrinogen (FIB) levels during tocilizumab (TCZ) treatment in patients with rheumatic diseases, to clarify the incidence of hypofibrinogenemia and its possible risk factors, and to establish a nomogram model for predicting the probability of hypofibrinogenemia in rheumatoid arthritis (RA) patients treated with TCZ.

Methods

Clinical data of patients treated with TCZ at the Department of Rheumatology and Immunology, the First Affiliated Hospital of Xi’an Jiaotong University from January 2014 to October 2021 were retrospectively analyzed to observe the incidence of hypofibrinogenemia in several rheumatic diseases at different time points. The risk factor of hypofibrinogenemia in RA patients treated with TCZ was determined by using Cox regression analysis. Based on the results of Cox regression analysis, a nomogram for predicting the probability of hypofibrinogenemia in rheumatoid arthritis (RA) patients treated with TCZ was established and validated through RStudio software.

Results

A total of 83 TCZ-treated patients were enrolled in this study, and 32 (38.55%) patients developed hypofibrinogenemia during TCZ treatment. There were 8 males and 24 females in the FIB-reduced group, with an average age of 44.88 ± 18.39 years. Hypofibrinogenemia was most common in TCZ-treated patients with takayasu arteritis (TA) and RA. Hypofibrinogenemia typically occured within 3 months after TCZ treatment. In RA patients treated with TCZ, platelet distribution width, parathyroid hormone, bone mineral density, tender joint count, and swollen joint count were independent risk factors for the occurrence of hypofibrinogenemia. The nomogram based on the above risk factors could effectively predict the probability of hypofibrinogenemia in RA patients receiving TCZ.

Conclusion

Although bleeding symptoms were not observed in this study, the incidence of hypofibrinogenemia remained high after TCZ treatment, usually occurring within 3 months of treatment. Therefore, it is necessary to monitor FIB levels during TCZ treatment. In addition, clinicians can use the nomogram model developed from this study to predict the incidence of hypofibrinogenemia after TCZ treatment in RA patients.

Key Points

• Hypofibrinogenemia often occurs during TCZ treatment for rheumatic diseases.

• PDW, PTH, BMD, tender joint count, and swollen joint count are risk factors for the occurrence of hypofibrinogenemia.

• It is necessary to monitor FIB levels during TCZ treatment to avoid bleeding tendency.

Nur mit Berechtigung zugänglich

Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T (2020) Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16:335–345. https://doi.org/10.1038/s41584-020-0419-zCrossRefPubMedPubMedCentral

Malaviya AP, Ledingham J, Bloxham J et al (2014) The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology (Oxford) 53:1344–1346. https://doi.org/10.1093/rheumatology/keu168CrossRefPubMed

Üsküdar Cansu D, Demirtaş E, Andiç N, Üsküdar Teke H, Korkmaz C (2019) Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review Rheumatol Int 39:743–750. https://doi.org/10.1007/s00296-019-04268-xCrossRefPubMed

Imamura H, Momohara S, Yano K, Sakuma Y, Nakayama M, Tobimatsu H, Ikari K (2018) Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty. Mod Rheumatol 28:976–980. https://doi.org/10.1080/14397595.2018.1428041CrossRefPubMed

Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Wakitani S, Koike T, Nakamura H (2016) Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int 36:349–357. https://doi.org/10.1007/s00296-015-3379-xCrossRefPubMed

McInnes IB, Thompson L, Giles JT et al (2015) Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 74:694–702. https://doi.org/10.1136/annrheumdis-2013-204345CrossRefPubMed

Kay J, Upchurch KS (2012) ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 51(Suppl 6):vi5-9. https://doi.org/10.1093/rheumatology/kes279CrossRefPubMed

Arend WP, Michel BA, Bloch DA et al (1990) The american college of rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134. https://doi.org/10.1002/art.1780330811CrossRefPubMed

Martini A, Ravelli A, Avcin T et al (2019) Toward new classification criteria for juvenile idiopathic arthritis: First steps, pediatric rheumatology international trials organization international consensus. J Rheumatol 46:190–197. https://doi.org/10.3899/jrheum.180168CrossRefPubMed

10.

van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755. https://doi.org/10.1136/annrheumdis-2013-204424CrossRefPubMed

11.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347. https://doi.org/10.1056/nejm197502132920706CrossRefPubMed

12.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407. https://doi.org/10.1056/nejm197502202920807CrossRefPubMed

13.

Yamaguchi M, Ohta A, Tsunematsu T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430PubMed

14.

Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P (2014) Adult-onset Still’s disease. Autoimmun Rev 13:708–722. https://doi.org/10.1016/j.autrev.2014.01.058CrossRefPubMed

15.

International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD) (2014) The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347. https://doi.org/10.1111/jdv.12107

16.

Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S (2014) The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun 48–49:50–52. https://doi.org/10.1016/j.jaut.2014.01.019CrossRefPubMed

17.

(1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874

18.

Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B (2017) Tocilizumab (Actemra). Hum Vaccin Immunother 13:1972–1988. https://doi.org/10.1080/21645515.2017.1316909CrossRefPubMedPubMedCentral

19.

Yokota S, Imagawa T, Mori M et al (2014) Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 41:759–767. https://doi.org/10.3899/jrheum.130690CrossRefPubMed

20.

Park EH, Lee EY, Shin K, Kim HA (2020) Tocilizumab-induced anaphylaxis in patients with adult-onset Still’s disease and systemic juvenile idiopathic arthritis: a case-based review. Rheumatol Int 40:791–798. https://doi.org/10.1007/s00296-019-04456-9CrossRefPubMed

21.

Souri M, Mokuda S, Inanami H, Osaki T, Takasugi K, Ichinose A (2016) Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab). Thromb Res 140:100–105. https://doi.org/10.1016/j.thromres.2016.02.026CrossRefPubMed

22.

He T, Ling J, Yang J (2023) Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis. Sci Rep 13:9050. https://doi.org/10.1038/s41598-023-36246-6CrossRefPubMedPubMedCentral

23.

Vitiello G, Orsi Battaglini C, Radice A, Carli G, Micheli S, Cammelli D (2017) Sustained tocilizumab-induced hypofibrinogenemia and thrombocytopenia. Comment on: "Tocilizumab-induced hypofibrinogenemia: a report of 7 cases" by Martis et al., Joint Bone Spine 2016. https://doi.org/10.1016/j.jbspin.2016.04.008. Joint Bone Spine 84:649–50. https://doi.org/10.1016/j.jbspin.2017.02.012

24.

Martis N, Chirio D, Queyrel-Moranne V, Zenut MC, Rocher F, Fuzibet JG (2017) Tocilizumab-induced hypofibrinogenemia: A report of 7 cases. Joint Bone Spine 84:369–370. https://doi.org/10.1016/j.jbspin.2016.04.008CrossRefPubMed

25.

Matsuoka M, Majima T, Onodera T et al (2012) Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis. Int J Hematol 96:781–785. https://doi.org/10.1007/s12185-012-1191-xCrossRefPubMed

Titel: Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia
verfasst von: Qi An
Rulan Ma
Dawei Yuan
Jing Huang
Jing Luo
Yanhua Wang
Ying Pan
Pei Wang
Xiaohong Lv
Dan Pu
Lan He
Publikationsdatum: 18.03.2024
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 5/2024
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-024-06937-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Geiser Sign in a patient with rheumatoid arthritis

Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis

Phenotypes of patients with systemic sclerosis in the Chinese Han population: a cluster analysis

Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia

Divergent perspectives: exploring the relationships between St. George’s Respiratory Questionnaire and outcome measures in systemic sclerosis–associated interstitial lung disease